{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:54:23Z","timestamp":1790258063609,"version":"4.1.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.neuropharm.2025.110450","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T01:01:25Z","timestamp":1743814885000},"page":"110450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Behavioral and transcriptomic effects of a novel cannabinoid on a rat valproic acid model of autism"],"prefix":"10.1016","volume":"273","author":[{"given":"Sally","family":"Loomis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7430-3037","authenticated-orcid":false,"given":"Diogo G.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjev","family":"Savopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Cilia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mat D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Virley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4863-1819","authenticated-orcid":false,"given":"Andrew","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0822-4514","authenticated-orcid":false,"given":"Emanuele","family":"Loro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"McCreary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2040-2392-4-36","article-title":"SFARI Gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (ASDs)","volume":"4","author":"Abrahams","year":"2013","journal-title":"Mol. Autism"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12888-019-2259-4","article-title":"Current state of evidence of cannabis utilization for treatment of autism spectrum disorders","volume":"19","author":"Agarwal","year":"2019","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110450_bib3","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.neuropharm.2025.110450_bib4","article-title":"Towards the convergent therapeutic potential of G protein-coupled receptors in autism spectrum disorders","author":"Annamneedi","year":"2023","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110450_bib5","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s10803-018-3808-2","article-title":"Brief report: cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral problems\u2014a retrospective feasibility study","volume":"49","author":"Aran","year":"2019","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.neuropharm.2025.110450_bib6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13229-019-0256-6","article-title":"Lower circulating endocannabinoid levels in children with autism spectrum disorder","volume":"10","author":"Aran","year":"2019","journal-title":"Mol. Autism"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13229-021-00420-2","article-title":"Cannabinoid treatment for autism: a proof-of-concept randomized trial","volume":"12","author":"Aran","year":"2021","journal-title":"Mol. Autism"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41598-018-37570-y","article-title":"Real life experience of medical cannabis treatment in autism: analysis of safety and efficacy","volume":"9","author":"Bar-Lev Schleider","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110450_bib9","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3389\/fphar.2018.01521","article-title":"Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and Co-morbidities","volume":"9","author":"Barchel","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13072-021-00432-5","article-title":"Changes in chromatin accessibility landscape and histone H3 core acetylation during valproic acid-induced differentiation of embryonic stem cells","volume":"14","author":"Baumann","year":"2021","journal-title":"Epigenetics Chromatin"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13229-018-0254-0","article-title":"Neuroglia in the autistic brain: evidence from a preclinical model","volume":"9","author":"Bronzuoli","year":"2018","journal-title":"Mol. Autism"},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110450_bib12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/gm102","article-title":"Genetic overlap between autism, schizophrenia and bipolar disorder","volume":"1","author":"Carroll","year":"2009","journal-title":"Genome Med."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110450_bib13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s13311-015-0371-9","article-title":"Endocannabinoid signaling in autism","volume":"12","author":"Chakrabarti","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000509109","article-title":"A systematic review of the valproic-acid-induced rodent model of autism","volume":"42","author":"Chaliha","year":"2020","journal-title":"Dev. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110450_bib15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.31887\/DCNS.2012.14.3\/pchaste","article-title":"Autism risk factors: genes, environment, and gene-environment interactions","volume":"14","author":"Chaste","year":"2012","journal-title":"Dialogues Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12035-023-03560-z","article-title":"Transcriptome analysis and epigenetics regulation in the Hippocampus and the prefrontal cortex of VPA-induced rat model","volume":"61","author":"Chen","year":"2024","journal-title":"Mol. Neurobiol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110450_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1469-8749.1994.tb11858.x","article-title":"Fetal valproate syndrome: clinical and neuro-developmental features in two sibling pairs","volume":"36","author":"Christianson","year":"1994","journal-title":"Dev. Med. Child Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110450_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21030723","article-title":"Phytocannabinoids in neurological diseases: could they restore a physiological GABAergic transmission?","volume":"21","author":"Cifelli","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib19","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nprot.2006.20","article-title":"Digging and marble burying in mice: simple methods for in vivo identification of biological impacts","volume":"1","author":"Deacon","year":"2006","journal-title":"Nat. Protoc."},{"issue":"26","key":"10.1016\/j.neuropharm.2025.110450_bib20","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1523\/JNEUROSCI.1712-06.2006","article-title":"The developmental neurobiology of autism spectrum disorder","volume":"26","author":"DiCicco-Bloom","year":"2006","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/joa.12542","article-title":"The neuroanatomy of autism \u2013 a developmental perspective","volume":"230","author":"Donovan","year":"2017","journal-title":"J. Anat."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamapsychiatry.2013.265","article-title":"Brain surface anatomy in adults with autism: the relationship between surface area, cortical thickness, and autistic symptoms","volume":"70","author":"Ecker","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neuropharm.2025.110450_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00304","article-title":"Current enlightenment about etiology and pharmacological treatment of autism spectrum disorder","volume":"12","author":"Eissa","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110450_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.110185","article-title":"Validation of prenatal versus postnatal valproic acid rat models of autism: a behavioral and neurobiological study","volume":"108","author":"Elnahas","year":"2021","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110450_bib25","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/aur.239","article-title":"Global prevalence of autism and other pervasive developmental disorders","volume":"5","author":"Elsabbagh","year":"2012","journal-title":"Autism Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02994-6","article-title":"Assessment of behavioral, morphological and electrophysiological changes in prenatal and postnatal valproate induced rat models of autism spectrum disorder","volume":"11","author":"Fereshetyan","year":"2021","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110450_bib27","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.neuropharm.2012.05.042","article-title":"Class I histone deacetylase inhibition ameliorates social cognition and cell adhesion molecule plasticity deficits in a rodent model of autism spectrum disorder","volume":"63","author":"Foley","year":"2012","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neures.2009.05.002","article-title":"Valproic acid induces up- or down-regulation of gene expression responsible for the neuronal excitation and inhibition in rat cortical neurons through its epigenetic actions","volume":"65","author":"Fukuchi","year":"2009","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.neuropharm.2025.110450_bib29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.psychres.2019.04.013","article-title":"Prevalence and predictors of psychotropic medication use in adolescents and adults with autism spectrum disorder in Italy: a cross-sectional study","volume":"276","author":"Fusar-Poli","year":"2019","journal-title":"Psychiatry Res."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110450_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci10090572","article-title":"Cannabinoids for people with ASD: a systematic review of published and ongoing studies","volume":"10","author":"Fusar-Poli","year":"2020","journal-title":"Brain Sci."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110450_bib31","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.biopsych.2010.09.031","article-title":"Validating \u03b3 oscillations and delayed auditory responses as translational biomarkers of autism","volume":"68","author":"Gandal","year":"2010","journal-title":"Biol. Psychiatry"},{"issue":"19","key":"10.1016\/j.neuropharm.2025.110450_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911917","article-title":"Association of NGF and mitochondrial respiration with autism spectrum disorder","volume":"23","author":"Gevezova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/aur.1263","article-title":"Exploring the relationship between anxiety and insistence on sameness in autism spectrum disorders","volume":"6","author":"Gotham","year":"2013","journal-title":"Autism Res."},{"issue":"18","key":"10.1016\/j.neuropharm.2025.110450_bib34","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex heatmaps reveal patterns and correlations in multidimensional genomic data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"10.1016\/j.neuropharm.2025.110450_bib35","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.euroneuro.2020.09.006","article-title":"Valproic acid exposure impairs ultrasonic communication in infant, adolescent and adult rats","volume":"41","author":"Gzielo","year":"2020","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"21","key":"10.1016\/j.neuropharm.2025.110450_bib36","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1007\/s00213-017-4703-9","article-title":"Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice","volume":"234","author":"Hara","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110450_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.951889","article-title":"Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: a placebo controlled randomized clinical trial","volume":"9","author":"Hermush","year":"2022","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/0269881117741766","article-title":"Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology","volume":"32","author":"Howes","year":"2018","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41392-022-01081-0","article-title":"Signalling pathways in autism spectrum disorder: mechanisms and therapeutic implications","volume":"7","author":"Jiang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110450_bib40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1527-3458.2003.tb00249.x","article-title":"Valproate: past, present, and future","volume":"9","author":"Johannessen","year":"2003","journal-title":"CNS Drug Rev."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrn.2015.8","article-title":"Neurobiology of rodent self-grooming and its value for translational neuroscience","volume":"17","author":"Kalueff","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110450_bib42","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13229-018-0203-y","article-title":"Plasma anandamide concentrations are lower in children with autism spectrum disorder","volume":"9","author":"Karhson","year":"2018","journal-title":"Mol. Autism"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1017\/S1461145711001714","article-title":"Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid","volume":"16","author":"Kataoka","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110450_bib44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bbr.2013.04.043","article-title":"Alterations in the endocannabinoid system in the rat valproic acid model of autism","volume":"249","author":"Kerr","year":"2013","journal-title":"Behav. Brain Res."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110450_bib45","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/acer.13484","article-title":"CRF(1) receptor-dependent increases in irritability-like behavior during abstinence from chronic intermittent ethanol vapor exposure","volume":"41","author":"Kimbrough","year":"2017","journal-title":"Alcohol Clin. Exp. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31921-5","article-title":"Adolescent cannabinoid exposure induces irritability-like behavior and cocaine cross-sensitization without affecting the escalation of cocaine self-administration in adulthood","volume":"8","author":"Kononoff","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110450_bib47","article-title":"A need for consistency in behavioral phenotyping for ASD: analysis of the valproic acid model","volume":"2021","author":"Larner","year":"2021","journal-title":"Autism Res Treat"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110450_bib48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.31887\/DCNS.2017.19.2\/wcarlezon","article-title":"Behavioral methods to study anxiety in rodents","volume":"19","author":"Lezak","year":"2017","journal-title":"Dialogues Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110450_bib49","doi-asserted-by":"crossref","first-page":"800","DOI":"10.24272\/j.issn.2095-8137.2021.251","article-title":"Understanding autism spectrum disorders with animal models: applications, insights, and perspectives","volume":"42","author":"Li","year":"2021","journal-title":"Zool. Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110450_bib50","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1369-1600.2008.00105.x","article-title":"The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction","volume":"13","author":"L\u00f3pez-Moreno","year":"2008","journal-title":"Addict. Biol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib51","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0301-0082(98)00075-6","article-title":"Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action","volume":"58","author":"L\u00f6scher","year":"1999","journal-title":"Prog. Neurobiol."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110450_bib52","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.neuropharm.2025.110450_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.859198","article-title":"Transcriptome analysis in Hippocampus of rats prenatally exposed to valproic acid and effects of intranasal treatment of oxytocin","volume":"13","author":"Matsuo","year":"2022","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2025.110450_bib54","series-title":"Irritability in Pediatric Psychopathology","article-title":"215C11Irritability in pediatric psychopathology: autism","author":"Mazefsky","year":"2019"},{"key":"10.1016\/j.neuropharm.2025.110450_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112966","article-title":"Valproic acid treated female Long-Evans rats are impaired on attentional set-shifting","volume":"397","author":"McKinnell","year":"2021","journal-title":"Behav. Brain Res."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110450_bib56","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1248\/cpb.36.3589","article-title":"Effect of sodium valproate (VPA) on cerebral amino acids: mechanism of gamma-aminobutyric acid (GABA) elevation and possible causal relation of VPA-induced encephalopathy and glutamine level","volume":"36","author":"Miyazaki","year":"1988","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.neuropharm.2025.110450_bib57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbr.2013.09.049","article-title":"Inhibition of histone deacetylase in utero causes sociability deficits in postnatal mice","volume":"257","author":"Moldrich","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2025.110450_bib58","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.neuro.2024.05.002","article-title":"Comparison of predictive validity of two autism spectrum disorder rat models: behavioural investigations","volume":"103","author":"Morel","year":"2024","journal-title":"Neurotoxicology"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110450_bib59","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.neuron.2015.07.033","article-title":"Excitatory\/inhibitory balance and circuit homeostasis in autism spectrum disorders","volume":"87","author":"Nelson","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2025.110450_bib60","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jpsychires.2021.02.048","article-title":"Potential of cannabinoids as treatments for autism spectrum disorders","volume":"137","author":"Nezgovorova","year":"2021","journal-title":"J. Psychiatr. Res."},{"issue":"Pt A","key":"10.1016\/j.neuropharm.2025.110450_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.expneurol.2017.04.017","article-title":"The valproic acid-induced rodent model of autism","volume":"299","author":"Nicolini","year":"2018","journal-title":"Exp. Neurol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110450_bib62","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1038\/s41380-022-01506-w","article-title":"Genetics of glutamate and its receptors in autism spectrum disorder","volume":"27","author":"Nisar","year":"2022","journal-title":"Mol. Psychiatr."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2025.110450_bib63","first-page":"17","article-title":"Pharmacology of valproate","volume":"37","author":"Owens","year":"2003","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.neuropharm.2025.110450_bib64","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pnpbp.2018.08.030","article-title":"Cannabidiol as a suggested candidate for treatment of autism spectrum disorder","volume":"89","author":"Poleg","year":"2019","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110450_bib65","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.chc.2008.06.010","article-title":"Developing drugs for core social and communication impairment in autism","volume":"17","author":"Posey","year":"2008","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1016\/j.neuropharm.2025.110450_bib66","series-title":"R: A Language and Environment for Statistical Computing","year":"2021"},{"key":"10.1016\/j.neuropharm.2025.110450_bib67","series-title":"Valproic Acid. StatPearls","author":"Rahman","year":"2024"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110450_bib68","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00787-023-02169-w","article-title":"Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review","volume":"33","author":"Rice","year":"2024","journal-title":"Eur. Child Adolesc. Psychiatr."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110450_bib69","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"\"limma powers differential expression analyses for RNA-sequencing and microarray studies.\"","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib70","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110450_bib71","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s00213-021-05851-6","article-title":"Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of autism spectrum disorder","volume":"238","author":"Rom\u00e1n","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2025.110450_bib72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ntt.2013.01.004","article-title":"In utero exposure to valproic acid and autism--a current review of clinical and animal studies","volume":"36","author":"Roullet","year":"2013","journal-title":"Neurotoxicol. Teratol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib73","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.npp.1300518","article-title":"Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism","volume":"30","author":"Schneider","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2025.110450_bib74","article-title":"Use of the Open Field Maze to measure locomotor and anxiety-like behavior in mice","volume":"96","author":"Seibenhener","year":"2015","journal-title":"J. Vis. Exp."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110450_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24081459","article-title":"Use of cannabidiol in the treatment of epilepsy: efficacy and security in clinical trials","volume":"24","author":"Silvestro","year":"2019","journal-title":"Molecules"},{"issue":"D1","key":"10.1016\/j.neuropharm.2025.110450_bib76","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"STRING v11: protein\u2013protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110450_bib77","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00401-017-1736-4","article-title":"Autism spectrum disorder: neuropathology and animal models","volume":"134","author":"Varghese","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110450_bib78","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s10803-006-0117-y","article-title":"A new neurobehavioral model of autism in mice: pre- and postnatal exposure to sodium valproate","volume":"36","author":"Wagner","year":"2006","journal-title":"J. Autism Dev. Disord."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110450_bib79","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/can.2015.0008","article-title":"Enhancement of anandamide-mediated endocannabinoid signaling corrects autism-related social impairment","volume":"1","author":"Wei","year":"2016","journal-title":"Cannabis Cannabinoid Res"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110450_bib80","article-title":"clusterProfiler 4.0: a universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110450_bib81","first-page":"459","article-title":"SZDB: a database for schizophrenia genetic research","volume":"43","author":"Wu","year":"2017","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110450_bib82","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/brainsci13050779","article-title":"Abnormal brain structure is associated with social and communication deficits in children with autism spectrum disorder: a voxel-based morphometry analysis","volume":"13","author":"Xu","year":"2023","journal-title":"Brain Sci."},{"issue":"7363","key":"10.1016\/j.neuropharm.2025.110450_bib83","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nature10360","article-title":"Neocortical excitation\/inhibition balance in information processing and social dysfunction","volume":"477","author":"Yizhar","year":"2011","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110450_bib84","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/aur.2696","article-title":"Global prevalence of autism: a systematic review update","volume":"15","author":"Zeidan","year":"2022","journal-title":"Autism Res."},{"key":"10.1016\/j.neuropharm.2025.110450_bib85","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3389\/fnmol.2018.00418","article-title":"Glutamate, glutamine and GABA levels in rat brain measured using MRS, HPLC and NMR methods in study of two models of autism","volume":"11","author":"Zieminska","year":"2018","journal-title":"Front. Mol. Neurosci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082500156X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082500156X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:32:10Z","timestamp":1778142730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082500156X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":85,"alternative-id":["S002839082500156X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110450","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Behavioral and transcriptomic effects of a novel cannabinoid on a rat valproic acid model of autism","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110450","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110450"}}